Trial Profile
A Randomized, Multi-centre, Efficacy Evaluation of PI-88 in Patients With Hepatocellular Carcinoma After Hepatectomy - A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Muparfostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cellxpert Biotechnology